It is with the greatest of sadness and the deepest of regret that Compassion Center announces the passing of its most beloved, precious, fearless, and courageous leader, Julie "Nurse Juhlzie" Monteiro (Creel), who peacefully transitioned of natural causes on November 11th, 2025, in the comfort, warmth, and sanctuary of her cozy king-sized bed.

Dr. Mohammed brings advanced training in wound care, sports injuries, and reconstructive foot and ankle surgery to two key metro Atlanta locations.

Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID

Company completed meeting with FDA October 2, 2025 for advice on possible expedited approval pathway to advance its ongoing placebo-controlled trial of crofelemer for potential approval for treatment of MVID

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment.

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~

~ Further Program Advancement Supported by Preferred Stock Financing ~

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -

- Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 -

With 6-figure expectations this one of one 2009 Topps Unique Tom Brady card featuring a game-worn NFL Equipment patch and autograph is now live at Fanatics Collect's Premier Auction that ends Thursday, November 20, 2025 at 9:30 PM Eastern Time (EST).

-Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump

- Aims to Improve Patient and Clinician Experience for the Care of Diabetes

Quarterly Results Reflect First Full Quarter Including Wattbike (Acquisition Closed July 1)

Company Reports Record Quarterly Revenue of $4.8 Million; Net Loss and Loss per Diluted Share of $5.2 Million and $3.11; Quarterly Adjusted EBITDA Loss of $2.9 million, Due to Low Inventory Availability

Sportstech Acquisition Expected to Close in 2025 Based on Key Closing Milestone Achievements

Reiterates 2025 Pro Forma Revenue Guidance of more than $80 million and Fourth Quarter Profitability Guidance

Outdoor toy-drive event rescheduled to prioritize safety as Las Vegas faces 70-90% chance of rain on Saturday

Total net revenue of $13.9 million

Net income of $2.0 million, or $0.21 net income per share basic

Adjusted EBITDA¹ of $(0.6) million, which includes EXXUA launch investments

$32.6 million cash balance at September 30, 2025

Company remains on track to launch EXXUA™ (gepirone) extended-release tablets ("EXXUA") in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market

Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time

Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive

Groundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID

Timed with a sharp acceleration in AI-data-center expansion, with more than $60B in new projects announced in the last 90 days.

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

11/12/2025 - Article updated to correct "Jim Krieg" to "James Kreig"

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action.

• Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers

• Integration of technology and physical infrastructure positions Wellgistics with the "Pharmacy IT Railroad" to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market

With a staggering 1405.46% revenue surge since February 2024, CBDL continues its explosive expansion as Smoking Scholars places another major order in New York's $7.2 billion cannabis market.

The physician-owned practice offers families comprehensive care, allowing patients to receive care for all of their medical needs at one of its 45-plus locations, with over 225 providers.

- Continued low early termination rate among the first 80 study completers suggests Halneuron^® and placebotreatmenthave been well tolerated

The best MTF top surgeon is Dr. Sajan

New cross-functional "Alpha Labs" team will fast-track AI and automation capabilities from concept to product, helping long-term care pharmacies work smarter, faster, and more efficiently.

DOHC strengthens its commitment to mothers and families through expanded education and personalized prenatal support

A very unique multi-vertical health AI engine capable of early detection for mental health, wound infection, skin cancer, and disease risk-all through a smartphone

First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting